Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cipher Pharmaceuticals Inc
Other Non-Cash Items
Cipher Pharmaceuticals Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Other Non-Cash Items
$116k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-34%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Non-Cash Items
$211m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other Non-Cash Items
CA$195.6m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other Non-Cash Items
$49m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other Non-Cash Items
$40.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
53%
|
CAGR 10-Years
100%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Non-Cash Items
CA$19.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's Other Non-Cash Items?
Other Non-Cash Items
116k
USD
Based on the financial report for Dec 31, 2025, Cipher Pharmaceuticals Inc's Other Non-Cash Items amounts to 116k USD.
What is Cipher Pharmaceuticals Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
-34%
Over the last year, the Other Non-Cash Items growth was -97%. The average annual Other Non-Cash Items growth rates for Cipher Pharmaceuticals Inc have been -26% over the past three years , -54% over the past five years , and -34% over the past ten years .
